Inhibrx Biosciences and Immuneering Compared in Financial Analysis

Examining the key metrics and performance of these two small-cap biotech companies

Published on Feb. 15, 2026

Got story updates? Submit your updates here. ›

Immuneering (NASDAQ:IMRX) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap medical companies operating in the biotech industry. This article provides a detailed financial comparison between the two firms, analyzing factors such as net margins, return on equity, institutional ownership, revenue, earnings, and stock volatility to determine which company is the better investment.

Why it matters

Investors looking to gain exposure to the biotech sector may be evaluating these two small-cap companies as potential investment opportunities. Understanding the key financial and operational differences between Immuneering and Inhibrx Biosciences can help inform investment decisions and provide insight into the relative strengths and weaknesses of each firm.

The details

The analysis finds that Inhibrx Biosciences has higher revenue and earnings than Immuneering, and is trading at a lower price-to-earnings ratio, indicating it may be the more affordable of the two stocks. Inhibrx also has stronger institutional ownership at 82.5% compared to 67.7% for Immuneering, suggesting greater backing from large investors. However, Inhibrx's stock is also more volatile, with a beta of 1.35 compared to Immuneering's beta of 0.46. Overall, the data shows Inhibrx Biosciences outperforming Immuneering on several key financial metrics.

  • The data and analysis in this article are current as of February 14, 2026.

The players

Immuneering Corporation

A clinical-stage oncology company developing medicines for cancer patients, including lead product candidates IMM-1-104 and IMM-6-415.

Inhibrx, Inc.

A clinical-stage biopharmaceutical company developing a pipeline of novel biologic therapeutic candidates, including INBRX-101, INBRX-109, and INBRX-106.

Got photos? Submit your photos here. ›

The takeaway

This analysis highlights the key financial and operational differences between Immuneering and Inhibrx Biosciences, two small-cap biotech firms vying for investor attention. While Inhibrx appears to have an edge in terms of revenue, earnings, and institutional backing, its higher stock volatility may give some investors pause. Ultimately, investors will need to weigh these factors carefully to determine which company presents the better long-term investment opportunity.